Todos os estudos
RecrutamentoFASE2INTERVENCIONISTA

A Study to Evaluate Safety and Explore Efficacy of New Lipase NHS7108 in Adult Participants With Exocrine Pancreatic Insufficiency.

This research study is looking into a new medication called NHS7108, which aims to help adults with Exocrine Pancreatic Insufficiency (EPI) digest their food better. The study will compare NHS7108 to Zenpep®, a common treatment for EPI, to understand its safety and how effectively it works. Participants will take both medicines at different times during the study, always as capsules with meals and snacks. Researchers will closely monitor how well fats and proteins are absorbed from food. The goal is to see if NHS7108 could be a helpful new option for managing EPI, including for those with Cystic Fibrosis or other pancreatic conditions.

Em resumo

Status
Recrutamento
Fase
FASE2
Patrocinador
Aimmune Nestlé Health Science US R&D, LLC
Meta de inscrição
66
Iniciar
01 Out 2026
Conclusão estimada
01 Set 2027

Sobre o que é este estudo?

This study is designed to explore a new medication, NHS7108, for adults who have a condition called Exocrine Pancreatic Insufficiency (EPI). EPI means your body doesn't make enough special juices (enzymes) in the pancreas to properly digest food, especially fats. This can lead to symptoms like stomach upset, bloating, and difficulty absorbing important nutrients. EPI can be caused by various issues, including Cystic Fibrosis (CF) or other pancreatic diseases.

The main goal of this study is twofold: first, to check how safe the new NHS7108 medicine is, and second, to see how well it helps people digest their food compared to a treatment already in use, called Zenpep®. Both NHS7108 and Zenpep® are capsules that participants will take with their daily meals and snacks. By carefully comparing these two treatments, researchers hope to understand if NHS7108 could be a valuable new option for managing EPI, potentially improving digestion and overall well-being for patients.

Participants will take different doses of NHS7108 and Zenpep® over specific periods, allowing the researchers to understand the effects across various strengths. During parts of the study, participants will follow a controlled diet, and special tests will be done to measure how much fat and protein their bodies are absorbing. This detailed approach will provide important information about how effective the new medicine is and help ensure that any potential new treatment is thoroughly evaluated for the benefit of future patients.

Pontos principais

  • Tests a new EPI medicine, NHS7108, against a standard treatment, Zenpep®.
  • Aims to check safety and how well it helps digest food.
  • Participants take both medicines at different times, as capsules with meals.
  • Involves controlled diet periods and stool collections to measure digestion.
  • Study lasts about 14 weeks for each participant.
  • Presents a potential new option for managing EPI.

Quem pode ser elegível?

To join this study, you need to be an adult between 18 and 85 years old. You must have a confirmed diagnosis of Exocrine Pancreatic Insufficiency (EPI) that is long-standing and not just a temporary issue. Your doctor must also agree that you need treatment for your EPI.

There are also some health checks. Your body mass index (BMI) should be between 17.0 and 35.0 kg/m² to ensure your digestion is reasonably stable. If you take other regular medications for conditions like infections or mucus problems, or for Cystic Fibrosis (like CFTR modulators), you can usually still participate, but you'll need to have been on a stable dose for a certain amount of time before the study starts and not change them during the study.

For contraception, if you are a man, you must agree to either avoid sex or use reliable birth control if your partner could become pregnant. If your partner is pregnant or breastfeeding, you must use a condom during sex. These rules are in place to ensure safety during the study.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Are you between 18 and 85 years old?
  2. Do you have a confirmed, ongoing diagnosis of Exocrine Pancreatic Insufficiency (EPI)?
  3. Is your doctor treating you for EPI?
  4. Are you able to maintain a stable dose of other regular medications (if any) during the study?
  5. If male, are you willing to follow specific contraception rules?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to take part, the study will last about 100 days (roughly 14 weeks). It starts with a screening period of up to 28 days (or possibly up to 56 days) to make sure you're a good fit. During this time, and at the end of each treatment period, you'll stay in a special setting for about 7 days. Here, you'll eat a carefully controlled diet with set amounts of fat and protein, and your stool will be collected. On the last day of these stays, a blood sample will be taken to measure fat absorption. This helps the researchers accurately check how well your body is digesting food.

During the main part of the study, you'll take study medication as capsules five times a day (with three main meals and two snacks). This will involve two treatment periods, each lasting about 14 days. You'll take NHS7108 during one period and Zenpep® during the other. Your usual pancreatic enzyme treatments will be paused for up to 8 days during screening and throughout both treatment periods. Outside of your supervised stays, you'll receive guidance to help you plan your meals and snacks at home according to your preferences.

After completing the treatment periods, there will be a final visit within 7 days of your last dose, and a safety check-up about 14 days later.

Riscos e benefícios potenciais

Participating in research studies like this always comes with potential benefits and risks. You might benefit from receiving close medical attention and access to a new experimental treatment for your EPI. It could also help researchers gain valuable knowledge that might lead to better treatments for others in the future. However, there may be side effects from the study medications, or the new medicine might not work for you as expected. The study procedures, like blood tests and stool collections, might also cause some discomfort or inconvenience. You are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Locations (39)

  • HonorHealth Research Institute
    Código postal verificado
    Scottsdale, Estados Unidos· Ainda não recrutando
  • University of Arkansas for Medical Sciences Hospital - University
    Código postal verificado
    Little Rock, Estados Unidos· Ainda não recrutando
  • Keck Hospital of USC
    Código postal verificado
    Los Angeles, Estados Unidos· Ainda não recrutando
  • Cedars Sinai Medical Center - Inflammatory Bowel Disease Ctr
    Código postal verificado
    Los Angeles, Estados Unidos· Ainda não recrutando
  • Omnicure Clinical Research
    Código postal verificado
    Doral, United States· Ainda não recrutando
  • Advent Health Medical Group
    Código postal verificado
    Orlando, Estados Unidos· Ainda não recrutando
  • Johnson County Clin-Trials (JCCT)
    Código postal verificado
    Lenexa, United States· Recrutamento
  • Johns Hopkins Medicine - Pulmonary and Critical Care
    Código postal verificado
    Baltimore, Estados Unidos· Ainda não recrutando
  • Billings Clinic Hospital - Public
    Código postal verificado
    Billings, United States· Ainda não recrutando
  • University Hospitals Cleveland Medical Center/Rainbow Babies & Children's Hospital
    Código postal verificado
    Cleveland, Estados Unidos· Ainda não recrutando
  • The Ohio State University College of Medicine (OSUCOM)
    Código postal verificado
    Columbus, Estados Unidos· Ainda não recrutando
  • University of Oklahoma Health Sciences Center - Pediatrics Hospital - University
    Código postal verificado
    Oklahoma City, Estados Unidos· Ainda não recrutando

Perguntas frequentes

What is Exocrine Pancreatic Insufficiency (EPI)?

EPI means your pancreas doesn't make enough enzymes to properly digest food, especially fats, which can lead to digestion problems.

What is the new medicine being tested?

The new medicine is called NHS7108. It's a capsule designed to help your body digest food, similar to your natural pancreatic enzymes.

Will I stop my current EPI medication?

Yes, you will need to pause your usual pancreatic enzyme treatment during parts of the study, specifically during screening and both treatment periods.

Quanto tempo estarei no estudo?

The total study will last for about 100 days, or roughly 14 weeks, including screening and follow-up.

What kind of tests will be done?

You'll have supervised stays where your diet is controlled, and stool samples will be collected. Blood tests will also measure how well you're digesting fats.

Como saber mais

Sandrine Guillot

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "A Study to Evaluate Safety and Explore Efficacy of New Lipas…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.